ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

US · FDA approval, new medicine

Camizestrant (Etcamah)

To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy

Approved 4 Sept 2026
EU · EU licence (European Commission)

Camizestrant (Etcamah)

Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine… Show the full indication

Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).

CHMP opinion 21 May 2026 → EU licence 20 Jul 2026 · AstraZeneca AB

Research

Oncology · Lancet Oncol · 2026-07-13

Extended analysis of a phase 3 trial in 315 patients with HR+/HER2− advanced breast cancer and ESR1 mutation in ctDNA before progression: switching to camizestrant vs continuing aromatase inhibitor (both with CDK4/6 inhibitor) gave median PFS 16·8 vs 9·2 months (HR 0·45).

RCTn = 315
Turner et al. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Oncology · J Clin Oncol · 2026-01-16

In a presurgical window trial of 132 postmenopausal women with ER-positive, HER2-negative early breast cancer, camizestrant at all doses cut tumour ER expression by about 65%; Ki67 fell more after 12–15 than 5–7 days. The 75 mg dose was well tolerated.

RCTn = 132 women
Robertson et al. Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.